A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

NCT05055258 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated by Sponsor due to adverse events reported

Conditions

Angioedema, Hereditary, Types I and II

Interventions

DRUG: KVD824
DRUG: Placebo to KVD824

Sponsor

KalVista Pharmaceuticals, Ltd.